IL13 and asthma: By targeting specific mediators of this inflammation, such as IgE, IL-5, IL-4, and IL-13, biologics aim to reduce severe asthma exacerbations, improve symptom control, and potentially reduce the need for systemic corticosteroids, thus mitigating their associated risks [12].